Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 16/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787929 | 0.95 | BDKRB1 (0.41) | BDKRB1CNR1JAK2JAK1BMPR1B | |
| Trifluoroacetic Acid SCHEMBL16194864 | 0.93 | BDKRB1 (0.40) | BDKRB1CNR1JAK2JAK1BMPR1B | |
| Trifluoroacetic Acid SCHEMBL3339973 | 0.92 | BDKRB1 (0.39) | BDKRB1CNR1JAK2JAK1BMPR1B | |
| Trifluoroacetic Acid SCHEMBL3339670 | 0.88 | BMPR1B (0.37) | JAK2JAK1BMPR1BBMPR1ATGFBR1 | |
| Trifluoroacetic Acid SCHEMBL3340083 | 0.87 | OPRM1 (0.41) | JAK2JAK1SLC2A1 | |
| SCHEMBL12651271 | 0.87 | PDCD1 (0.41) | BDKRB1CNR1JAK2JAK1BMPR1B | |
| SCHEMBL12651510 | 0.86 | BDKRB1 (0.40) | BDKRB1CNR1JAK2JAK1BMPR1B | |
| Trifluoroacetic Acid SCHEMBL3340014 | 0.85 | CTSC (0.44) | BDKRB1CNR1BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL1784811 | 0.82 | OPRM1 (0.44) | JAK2JAK1 | |
| SCHEMBL12651164 | 0.82 | BMPR1B (0.38) | JAK2JAK1BMPR1BBMPR1ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | BDKRB1 177/4885CNR1 43/4885JAK2 723/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | BDKRB1 163/4885CNR1 22/4885JAK2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.